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The role of caspases and calpains in neurodegenera-
tion remains unclear. In this study, we focused on these
proteases in a rat model of Huntington’s disease using
the mitochondrial toxin 3-nitropropionic acid (3NP). Re-
sults showed that 3NP-induced death of striatal neurons
was preceded by cytochrome c redistribution, transient
caspase-9 processing, and activation of calpain, whereas
levels of the active/processed form of caspase-3 re-
mained low and were even reduced as compared with
control animals. We evidenced here that this decrease in
active caspase-3 levels could be attributed to calpain
activation. Several observations supported this conclu-
sion. 1) Pharmacological blockade of calpain in 3NP-
treated rats increased the levels of endogenous pro-
cessed caspase-9 and caspase-3. 2) Cell-free extracts
prepared from the striatum of 3NP-treated rats de-
graded in vitro the p34 and p20 subunits of active recom-
binant caspase-9 and caspase-3, respectively. 3) This
degradation of p34 and p20 could be mimicked by puri-
fied -calpain and was prevented by calpain inhibitors.
4) -Calpain produced a loss of the DEVDase (Asp-Glu-
Val-Asp) activity of active caspase-3. 5) Western blot
analysis and experiments with 35S-radiolabeled
caspase-3 showed that -calpain cleaved the p20 subunit
of active caspase-3 near its catalytic site. 6) -Calpain
activity was selectively inhibited (IC50 of 100 M) by a 12
amino acid peptide corresponding to the C terminus of
p20. Our results showed that calpain can down-regulate
the caspase-9/caspase-3 cell death pathway during neu-
rodegeneration due to chronic mitochondrial defects in
vivo and that this effect may involve, at least in part,
direct cleavage of the caspase-3 p20 subunit.
Several evidences demonstrate the role of excitotoxic cell
death and mitochondrial defects in neurodegenerative diseases
(1). This hypothesis is strongly supported for Huntington’s
disease (HD),1 an inherited neurodegenerative disorder caused
by an abnormal expansion of a polyglutamine tract in the
huntingtin (Htt) protein (2). HD is characterized by involun-
tary choreiform movements and cognitive deficits (3). The most
striking neuropathological characteristic of this disorder is
preferential atrophy of the striatum due to death of medium
size spiny neurons (3).
The involvement of excitotoxicity in HD was initially sup-
ported by observations that several histological and behavioral
anomalies of HD can be mimicked in rats and non-human
primates by intrastriatal injection of agonists of the glutamate
receptors (4), in particular quinolinate, an agonist of the N-
methyl-D-aspartate (NMDA) subtype of glutamate receptors (5,
6). Anomalies in the NMDA-evoked current amplitude have
been observed in transgenic mice for the mutated full-length
Htt, further substantiating the “excitotoxic” hypothesis (7, 8).
In addition, the striatum in these HD transgenic mice exhibits
increased vulnerability to the toxicity of quinolinate (8).
It has been suggested that excitotoxic neuronal death could
be an indirect consequence of the chronic mitochondrial anom-
alies that have consistently been reported in HD patients (9,
10). Thus, decreases in the activity of respiratory chain com-
plex II (11, 12) and increases in lactate concentrations have
been evidenced in the striatum of HD patients (13). Mitochon-
dria from lymphoblasts of HD patient also display increased
vulnerability to apoptotic stimuli (14), anomalies in mito-
chondrial membrane potential, and defect in Ca2-buffering
capacity (15).
Observations using the mitochondrial toxin 3-nitropropionic
acid (3NP), an irreversible inhibitor of succinate dehydrogen-
ase/complex II (16), also support the so-called “indirect excito-
toxic” hypothesis for HD. Indeed, chronic systemic administra-
tion of 3NP in rats and non-human primates produces
homogenous blockade of complex II within the brain (17), lead-
ing to preferential excitotoxic striatal degeneration associated
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with behavioral abnormalities that are highly reminiscent of
HD (18–20).
Despite numerous published studies, the cell death mecha-
nisms underlying 3NP neurotoxicity in vivo are not fully un-
derstood (21). We recently examined the involvement of death
proteases of the caspase family and Ca2-activated neutral
protease calpains in 3NP toxicity in rats (22). Interestingly, we
found that when 3NP was administered to produce a chronic/
steady mitochondrial perturbation, caspase-9 was transiently
activated but surprisingly without being followed by an in-
creased activation of caspase-3. In contrast, abnormal activa-
tion of the Ca2-activated neutral protease calpain was ob-
served in the striatum of 3NP-treated rats (22), as seen in the
striatum of HD patients (23). The reasons that could account
for the predominance of calpain over caspase-3 despite a tran-
sient activation of caspase-9 in the 3NP model of degeneration
remained speculative assumptions (22).
In this study, we further examined the mechanisms involved
in the predominance of calpain over caspase-3 activation in the
chronic 3NP model of HD. Because elegant experiments re-
cently demonstrated the existence of a complex cross-talk be-
tween calpains and caspases (24–27), we hypothesized that
calpain could play an important role in the stoppage of the
mitochondrial caspase pathway in this chronic 3NP lesion
model. Using this model, we re-examined the time course of
activation of calpain and caspase-9 and caspase-3 and we stud-
ied how calpain could modify the caspase-9/caspase-3 pathway
in vivo and in vitro. We provide hereforth the biochemical and
pharmacological evidences that in this model calpain inacti-
vates the caspase-9/caspase-3 pathway through, at least partly,
direct proteolysis of their active forms. In particular, calpain
inactivates active caspase-3 by cleaving the C terminus domain
of its p20 subunit.
MATERIALS AND METHODS
Animals—Because 3NP toxicity is age-dependent (28), all of the
experiments were carried out in 12-week-old male Lewis rats (IFFA
Credo, L’Arbresle, France) weighing 340–370 g. Experimental proce-
dures were performed in strict compliance with the recommendations of
the European Community (86/609/EEC) and the French National Com-
mittee (87/848) for care and use of laboratory animals.
Chemical and Reagents—All of the chemicals and reagents were
purchased from Sigma unless specified.
3NP Treatment and Experimental Design—As described previously,
a solution of 3NP was systemically delivered by chronic infusion (54
mg/kg/day) using osmotic mini-pumps (flow rate 10 l/h, model 2ML1,
Alzet Inc, Palo Alto, CA) placed subcutaneously in the back of the rats
under ketamine-xylazine anesthesia (22, 29, 30). Control rats were
sham-operated. Groups of rats (n  5–8) were killed by decapitation at
daily intervals (days 1, 2, 3, 4, and 5) after osmotic pump implantation
(day 0). In one experiment, animals (n 5/time point) were killed every
6 h from day 2 to 5.
Motor Score—Animals were observed daily to detect the occurrence
of motor symptoms. Each animal was scored using a neurological scale
(normal  0, very symptomatic  8) as previously described (29, 30).
Calpain Inhibitor I Neuroprotection Experiments in the Chronic
Model—The calpain inhibitor I (CI-1, z-Leu-Leu-Norleucinal, Biomol,
Plymouth Meeting, PA) solubilized in dimethyl sulfoxide (40%) and
diluted in phosphate-buffered saline was delivered (infusion rate 2.5
g l1h1) by intra-cerebroventricular infusion using an osmotic
mini-pump (Model 2001, Alzet) connected to a stereotaxically implanted
cannula (antero-posterior  1.6 mm; lateral  2.0 mm from Bregma;
ventral  3.5 mm from Dura; “brain infusion kit,” Alzet) (22). The
osmotic pump delivering CI-1 and that delivering 3NP were implanted
simultaneously. Biochemical analyses were performed on day 5 of the
neurotoxic treatment.
Brain Processing, Sample Dissection, and Homogenization—Brains
were rapidly removed from the skull and cut vertically along the rostro-
caudal axis into two hemispheres. The left hemisphere was fixed in
Bouin’s solution for 3 days and paraffin-embedded for immunohisto-
chemical evaluation. Striatum samples were dissected from the right
hemisphere and processed for biochemical analyses. Tissue dissection
and processing were performed at 4 °C. The lateral striatum was dis-
sected out of a 2-mm-thick coronal slice. Tissue samples (10–20 mg)
were homogenized using a 1-ml glass Teflon potter (900 rpm, 20
strokes) in 300 l of buffer containing protease inhibitor mixture (Com-
plete, Roche Applied Science). For cytochrome c (cyt c) redistribution
studies, homogenization was performed in buffer A preserving mito-
chondria (10 mM HEPES-KOH, pH 7.4, 60 mM sucrose, 210 mM man-
nitol, 5 mM EGTA, 1 mM EDTA, 10 mM KCl, 10 mM succinate, and 1 mM
ADP). For evaluation of caspase-3 and caspase-9 and calpain activities
during the course of the 3NP treatment, homogenization was performed
in buffer B containing 250 mM sucrose, 1 mM EDTA, 50 mM Tris-HCl,
pH 7.4, and 1 mM dithiothreitol as previously described (31). Homoge-
nate was first centrifuged at 1000  g for 5 min. The post-nuclear
supernatant was centrifuged at 15,000  g for 30 min, the resulting
pellet containing the mitochondria fraction. The supernatant was fur-
ther centrifuged at 100,000  g for 30 min. The resulting high speed
supernatant contained the cytosol fraction, whereas the high speed
pellet contained the membrane fraction. In cell-free extract studies
examining calpain/caspase cross-talk, fractions enriched in cytosol were
prepared by homogenization in a buffer C containing 25 mM HEPES-
KOH, pH 7.4, 0.1% Triton X-100, 5 mM MgCl2, 1.3 mM EDTA, and 1 mM
EGTA (22). This homogenate was centrifuged at 15,000  g for 30 min,
giving a cell-free extract (supernatant) and a membrane-enriched frac-
tion (pellet). This procedure led to essentially similar results in terms of
protease activities when compared with the use of buffer B with a
three-step centrifugation. All of the fractions were stored at 80 °C
until analysis.
Histological Studies—Hoechst nuclear staining with bis-benzimide
H33258 and histochemistry for cyt c (primary antibody against cyt c,
BD Biosciences) were performed on paraffin sections as described pre-
viously (22, 32). Histochemistry of succinate dehydrogenase (SDH) was
performed and quantitatively analyzed according to previously pub-
lished procedures (17, 22, 29).
Western Blot Analysis—Protein concentrations were determined us-
ing the BCA method (Pierce) according to the manufacturer’s instruc-
tions. Proteins in striatal samples were separated by SDS-PAGE as
described previously (22). Following blot transfer, nitrocellulose mem-
branes were incubated overnight at 4 °C with one of the antibodies
raised against the following: fodrin (1:2000, antibody against non-eryth-
roid -spectrin, Chemicon, Temecula, CA), cytochrome c (1:2000; BD
Biosciences, San Diego, CA), calbindin D28k (1:1000, monoclonal, Sig-
ma), caspase-9 (1:1000, rabbit polyclonal Bur 81, Burnham Institute)
(32), and C-terminal domain of active caspase-3 p20 subunit (1:1000,
rabbit polyclonal antibody 1797, Cell Signaling Technology, Beverly,
MA). After incubation with the primary antibody, the blots were incu-
bated with horseradish peroxidase-conjugated anti-mouse or anti-rab-
bit IgG (1:1000, Sigma) and peroxidase activity was detected using ECL
reagent (Amersham Biosciences). For detection of active caspase-3 in
cytosolic fractions of the striatum of 3NP-treated rats prepared by
ultracentrifugation (see time-course study in Fig. 3), secondary anti-
body was used at 1:5000 dilution and peroxidase activity was detected
using Femto-ECL reagent (Pierce).
Oligonucleosome Detection—Oligonucleosome contents in soluble
fractions (20 l) were determined using the enzyme-linked immunosor-
bent assay cell death detection kit (Roche Applied Science) according to
the manufacturer’s instructions. The results were normalized by the
protein concentration in each sample and expressed as mean the optical
density values  S.E.
Proteolytic Activity Assay Using Fluorogenic Substrate for Caspase
and Calpain—The fluorescent assay of proteases is based on the cleav-
age of 7-amino-4-methyl-coumarin (AMC) or 7-amino-4-trifluoro-meth-
yl-coumarin (AFC) dyes from the C terminus of the peptide substrates
(22). The calpain activity was determined using N-succinyl-Leu-Tyr-(N-
succinyl-LY)-AMC, a substrate preferentially cleaved by -calpain and
m-calpain (33). Calpain activity (Ca2-dependent cleavage of N-succi-
nyl-LY-AMC) present in cytosol fraction (10 l containing 30 g of
protein) was determined as the difference between the calcium-depend-
ent and the non-calcium-dependent fluorescence. The calcium-depend-
ent fluorescence released was measured after a 30-min incubation at
37 °C in buffer D containing 63 mM imidazole-HCl, pH 7.3, 10 mM
-mercaptoethanol, and 5 mM CaCl2 and is attributable to the cleavage
of 150 M N-succinyl-LY-AMC. The non-calcium-dependent fluores-
cence was measured under the same conditions using buffer D without
calcium and containing 1 mM EDTA and 10 mM EGTA. Using the
fluorometric assay described above, we performed in vitro concentration-
dependent inhibition experiments of calpain activity (purified -cal-
pain, 0.2 units/well, Calbiochem) with the synthetic peptide correspond-
ing to the 12 amino acids of the C terminus of caspase-3 p20 (Ct12p20,
Calpain/Caspase-3 Cross-talk during Neurodegeneration43246
 at CEA
 Saclay on Septem
ber 17, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
RGTELDCGIETD), a scramble peptide (ICDLGTEDRTEG), and a pep-
tide with leucine 168 substituted by a lysine (Ct12p20-L168K, RGTEK-
DCGIETD) solubilized at 10 mM (90% pure) in water.
Caspases-3, -8, and -9 activities were tested on peptidic substrates
(Biomol) using, respectively, N-acetyl-Asp-Glu-Val-Asp-AFC (DEVD-
AFC), N-acetyl-Ile-Glu-Thr-Asp-AFC (IETD-AFC) and N-acetyl-Leu-
Glu-His-Asp-AFC (LEHD-AFC). Soluble fractions (30 g of protein)
were incubated at 37 °C for 45 min in caspase buffer E (20 mM HEPES,
pH 7.4, 50 mM NaCl, 0.2 mM EDTA, and 4 mM dithiothreitol) with 40 M
of the appropriate substrate. The nonspecific activity was measured in
the presence of 10 M of the appropriate caspase inhibitor i.e. the
C-terminal aldehyde form (CHO) of the substrate (DEVD-CHO, IETD-
CHO, and LEHD-CHO for caspases-3, -8 and –9, respectively). Fluores-
cence (excitation/emission: 400/505 nm for AFC and 380/460 nm for
AMC) was measured in 96-well plates using a “Fusion” fluorometer
(PerkinElmer Life Science). Enzyme activity was calculated using
standard curves of AFC or AMC and expressed as the mean activity 
S.E. (picomole of AFC-AMC releasedmin1mg1 protein).
Degradation of Recombinant Caspases in Vitro and ex Vivo by Puri-
fied Calpain and Striatal Extracts from 3NP-treated Rats—We studied
the in vitro proteolysis (1 h at 37 °C) of each recombinant human
caspase (-3, -8, and -9) (50 ng for Western blot analysis and 10 ng for
proteolysis activity assay, Biomol) by purified -calpain (0.2 units) in
100 l of buffer D (with calcium). Cleavage of recombinant caspases was
also studied after a 1-h incubation with cell-free extract of striatal
homogenate from control or 3NP-treated rats (20 g of protein). Diges-
tion products were analyzed by 8–20% gradient SDS-PAGE followed by
Western blot analysis. In addition, the functional effects of purified
calpain and striatal extracts on recombinant caspases were quantita-
tively assessed by determining DEVDase and IETDase proteolytic ac-
tivities related to active recombinant caspases-3 and -8, respectively. To
detect the cleavage products of caspase-3 by calpain, we produced
histidine-tagged and [35S]methionine-labeled procaspase-3 using a rab-
bit reticulocyte lysate system (TNT quick coupled transcription/trans-
lation system, Promega) and a pET-15b-procaspase-3 construct. The
pET-15b-procaspase-3 construct was generated as described previously
(34). 35S-Labeled caspase-3 protein was digested with recombinant
caspase-8 (50 ng, Biomol) for maturation into its active form containing
the p20 subunit. 35S-Labeled p20 then was subjected to calpain diges-
tion as described above. When stated, the calpain inhibitor CI-1 (10 M)
was added to the reaction. Reaction products were analyzed by SDS-
PAGE. Following treatment with Amplify (Amersham Biosciences) and
drying of gels, 35S-labeled proteins were visualized by autoradiography.
Statistical Analysis—Results were expressed as the means  S.E.
Statistical analysis included Student’s t test or ANOVA followed by a
post hoc Scheffe´ F-test (StatView, version 5.0, Berkeley, CA).
RESULTS
Time Course of Behavioral, Histological, and Biochemical
Changes Produced in the Striatum by Chronic 3NP Treat-
ment—In agreement with previously reported experiments
(22, 29, 30), the onset of overt motor symptoms (bilateral
dystonia, uncoordinated movements, bradykinesia, and gait
abnormalities) occurred on day 3 of 3NP treatment (Fig. 1A).
In the experiment presented in Fig 1A, symptoms worsened
on day 4 and reached their maximal severity on day 5. The
analysis of SDH activity in the brain showed that after day 3
constant administration of 3NP produced a partial and con-
stant mitochondrial defect very similar to that observed in
HD (Fig. 1B). Histological evaluation of the striatum at var-
ious times during 3NP treatment showed overt tissue abnor-
malities in all of the animals after day 4. The nuclei of
striatal cells were often fragmented as seen with Hoechst
staining (Fig. 1C). Consistent with this finding, cytosolic
fraction of striatal homogenates showed significant eleva-
tions in free oligonucleosome levels, indicating DNA frag-
mentation beginning at day 4  12 h and continuing there-
after (Fig. 1D).
We analyzed the “mitochondrial” apoptosis pathway in the
striatum of 3NP-treated rats. The cellular distribution of cyt c
in the striatum was modified during 3NP treatment as it is
observed during apoptosis. Cyt c was barely detectable in the
cytosolic fraction of striatal homogenates from control rats. In
contrast, cytosol fraction from 3NP-treated rats showed a
marked and transient increase in cyt c on day 2, i.e. 3 days
before the onset of striatal degeneration (Fig. 2A). Consistent
with this observation, immunohistochemistry of cyt c with
Nissl counterstaining showed accumulation of immunoreactiv-
ity in the perikarya of neurons (Fig. 2B). We next assessed the
occurrence of caspase-9 and -3 activation in the 3NP model.
Striatal cytosolic fractions from animals on days 2 and 3
showed a slight increase in the zymogen (p46) and processed
form of caspase-9 (p34) compared with the base-line levels
observed in controls (Fig. 2C). Measurement of caspase-9-re-
lated LEHDase activity in the striatum of 3NP rats showed
FIG. 1. Mitochondrial defects and striatal degeneration pro-
duced by chronic 3NP administration. Adult Lewis rats were sys-
temically treated with 3NP and were assessed at the indicated time for
motor symptoms and histological and biochemical changes. A, 3NP-
induced motor symptoms. Obvious symptoms (hind limb dystonia) were
observed on day 3 and worsened thereafter to reach a maximum on day
5. Each point corresponds to the mean value of motor index  S.E. in
5–6 animals. For explanation of motor index, see “Materials and Meth-
ods.” B, 3NP-induced inhibition of brain SDH activity. Upper panels,
representative coronal rat brain sections revealed for SDH histochem-
istry from control (CTRL) and from rats at day 5 of 3NP treatment. Note
the reduction of SDH activity in the entire brain. Pallor (arrow) within
the striatum is due to ongoing neurodegeneration and 3NP-induced
SDH blockade. Lower panel, the curve represents quantification of SDH
activity in the cerebral cortex (see white delineated regions in upper
panel), indicating that after 2–3 days of treatment, enzyme inhibition
reaches65% and remains constant thereafter. Each point corresponds
to the mean value S.E. in 6–7 animals. *, p  0.0001 compared with
control, ANOVA, and post-hoc Scheffe´ F-test. C, nuclear abnormal
morphology in the striatum of 3NP-treated rats. In control rats, Ho-
echst staining shows diffuse fluorescence through the nuclei of striatal
neurons (left panels, CTRL). In 3NP-treated rats (day 5), the staining
often shows fragmented nuclei (right panels, three representative ex-
amples) (scale bar, 10 m). D, nuclear DNA fragmentation in the
striatum during 3NP treatment evaluated by the presence of free oli-
gonucleosomes in the soluble fraction of striatum homogenates. CTRLs
are represented by the dashed line. Each point corresponds to the mean
value S.E. determined every 6 h in 5–6 animals. *, p  0.0001
compared with control, ANOVA, and post-hoc Scheffe´ F-test.
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significant increase on day 3, consistent with a transient
activation of caspase-9 (Fig. 2D). We next examined the sta-
tus of caspase-3, which is activated downstream of caspase-9.
Surprisingly, Western blot analysis showed an apparent loss
of the active caspase-3 subunit p20 (seen as 17/19-kDa dou-
blet) in the striatum of 3NP-treated animals on days 4 and 5
(Fig. 3A). In line with this finding, fluorometric measure-
ments of DEVDase proteolytic activity in the striatal cytoso-
lic fraction showed no activation of effector caspase-3 in 3NP-
treated rats when compared with sham animals (Fig. 3B).
Moreover, caspase-3-related proteolytic activity decreased
during treatment (Fig. 3B).
As reported previously (22), Western blot analysis for fodrin
(non-erythroid -spectrin), a known substrate of both caspase-3
and calpain (35), showed a progressive accumulation of cal-
pain-mediated fodrin breakdown products, which appeared as
a 150/145-kDa doublet, during 3NP treatment (Fig. 3C). The
caspase-3-dependent 120-kDa breakdown product was not de-
tected. On day 4, in the striatum of the 3NP-treated rats
analyzed above for activation of caspases-3 and -9, the Ca2-
dependent calpain-related activity revealed by the cleavage of
the fluorogenic calpain substrate N-succinyl-LY-AMC was sig-
nificantly increased (145%, p  0.0003) compared with con-
trols. In this experimental group of animals on day 5, calpain-
related proteolytic activity was near control value (34%, non
significant, Fig. 3D), whereas in other experiments calpain
activity remained significantly increased on day 5.2 Thus, there
is a modest interexperiment variability with regards to the
duration of calpain-related proteolytic activity due to 3-NP
intoxication in vivo. Nevertheless, our results demonstrate the
occurrence of activation of calpain associated with 3NP-in-
duced mitochondrial defects.
Degradation of Caspase-9 and Caspase-3 by Calpain—Be-
cause during the course of 3NP-induced changes the loss of
caspase-3 p20 subunit occurred despite cyt c redistribution and
caspase-9 activation and was concurrent with the increase in
calpain activity, we reasoned that calpain could be responsible
for the lack of caspase-3 activation. To test this hypothesis in
the striatum of 3NP-treated rats, we studied the effects of
intracerebral infusion of the CI-1 on the endogenous levels of
p20 and p34 subunits of caspases-3 and -9, respectively (Fig. 4).
In this experiment, we analyzed the animals on day 5 of the
3NP treatment. In 3NP-treated rats, CI-1 infusion induced an
increase in the levels of endogenous caspase-9 p34 subunit
compared with control rats or 3NP-rats infused with CI-1 ve-
hicle (Fig. 4A). In vivo CI-1 infusion also prevented the loss of
endogenous caspase-3 p20 subunit induced by 3NP as shown by
Western blot using an antibody recognizing the C-terminal
domain of the p20 subunit of caspase-3 (Fig. 4B). Consistently,
the endogenous DEVDase activity of striatal extracts was sig-
nificantly reduced by 57% (p  0.006) with the 3NP treatment.
This reduction of activity was completely reversed to control
values by in vivo CI-1 infusion (Fig. 4C). Altogether, our results
demonstrated an inhibitory effect of calpain on caspase-3 ac-
tivity. Therefore, we hypothesized that this inhibitory effect
could result from a direct cleavage of caspases-9 and -3 by
calpain.
Thus, we examined the degradation of the active subunits of
caspases-9 and -3 in cell-free extracts prepared from the stria-
tum of control and 3NP-treated rats on day 5 that were infused
with CI-1 or vehicle. Striatal extracts from 3NP-treated rats
infused with vehicle showed a significant increase in calpain
activity compared with extract prepared from control rats
(AMC released in pmolmin1mg1 control: 20.51  0.37;
3NP/vehicle: 29.37 0.71,43% versus control, p 0.0002). In
3NP-treated rats injected with CI-1, calpain activity was sig-
nificantly inhibited compared with controls (AMC released
5.92  0.78 pmolmin1mg1, p  0.0001) and 3NP-treated
rats injected with vehicle (data not shown). Recombinant
caspases-9 and -3 were incubated with these extracts and then
analyzed by Western blot. Extracts from 3NP rats induced a
loss of recombinant caspase-9 subunit p34 (Fig. 5A), whereas
control extracts produced no effect. Similarly, incubation of
recombinant caspase-3 with striatal extract from 3NP-treated
rats produced a loss of the caspase-3 subunit p20 (i.e. 19/17-
kDa doublet) (Fig. 5B). In line with this finding, DEVDase
activity of the recombinant caspase-3 was reduced to 68% fol-
lowing incubation with striatal extracts from 3NP-treated rats
as compared with striatal extracts from control rats (Fig. 5B).
2 D. Blum, M. F. Beal, L. Yang, N. Bizat, J.-M. Hermel, and E.
Brouillet, unpublished results.
FIG. 2. Activation of the mitochondrial pathway in the striatum of
3NP-treated rats. Cyt c redistribution and transient caspase-9 activation
during 3NP treatment. A, SDS-PAGE followed by Western blot for cyt c and
calbindin D28K of striatal cytosol prepared from control (CTRL) and 3NP-
treated rats. Note that in the cytosol of 3NP-treated rats, cyt c immunore-
activity transiently increases on days 1 and 2, whereas the neuronal marker
calbindin remains stable, indicating an equal protein loading in each lane
and consistent with an absence of neurodegeneration at these early time
points. Results are typical of three independent experiments. B, immuno-
histochemistry of cytochrome c shows rare punctate labeling within the
perikarya of striatal cells in control animals, whereas it increases in the
perikarya in 3NP-treated rats (arrows). Nucleus is seen in blue after Cresyl
violet counterstaining. C, Western blot of striatal homogenates for caspase-9
reveals a slight and transient increase in the zymogene (p46) and active
form of caspase-9 (p34) on days 2 and 3. Recombinant activated caspase-9
(Rec. C9) mixed with control cytosol was loaded as a positive control in the
left lane. D, LEHDase proteolytic activity during the 3NP treatment shows
transient activation of caspase-9 at day 3. Each point corresponds to the
mean valueS.E. determined in triplicate and corresponds to 3–4 animals/
day. *, p  0.0001 compared with control, ANOVA, and post-hoc Scheffe´
F-test.
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This loss of detection of active/processed caspases-3 and -9
produced by striatal extract of 3NP-treated rats was signifi-
cantly reduced by the addition of the selective calpain inhibitor
z-LL-CHO in vitro or by delivering in vivo CI-1 during the 3NP
treatment (Fig. 5). Similarly, the loss of DEVDase activity
induced by striatal extracts was also prevented by z-LL-CHO
incubation and CI-1 treatment (Fig. 5). These results indicated
that calpain could be responsible for the degradation of
caspases-9 and -3 in the striatum of 3NP-treated rats, probably
through a cleavage of the active/processed forms of the
caspases.
We next assessed the possibility of a direct in vitro cleavage
of recombinant caspases-9 and -3 by incubation with purified
-calpain. After SDS-PAGE resolution of the products, West-
ern blot analyses showed that calpain degraded the p34 sub-
unit of human active recombinant caspase-9 (Fig. 6A), in agree-
ment with previous reports (25). After incubation with
-calpain, active recombinant caspases-3, i.e. the p17/19 dou-
blet, was no longer detected by Western blot using an antibody
recognizing the C-terminal domain of the p20 subunit (Fig. 6B).
No caspase-3 fragment smaller than 17 kDa was detected,
suggesting a digestion of this epitope. The cleavage of active
recombinant caspase-3 by -calpain was correlated with a loss
of its DEVDase proteolytic activity (Fig. 6C). Both the loss of
immunoreactivity by Western blot and DEVDase activity were
reversed by incubation of calpain with its inhibitor Cl-1. In
contrast, using the same incubation conditions, calpain pro-
duced no effects upon the IETDase activity of recombinant
active caspase-8 (data not shown). Because we showed that
antibodies directed against the C-terminal domain of p20 could
no longer recognize the protein after calpain-mediated cleavage
and that cleavage produced a loss of proteolytic activity, we
hypothesized that the site of cleavage on p20 was near its
catalytic site at the C terminus of the peptide and that the
C-terminal domain of p20 interacts with calpain. To test this
hypothesis, we studied whether a synthetic peptide correspond-
ing to the C-terminal 12 amino acids of p20 (Ct12p20) could
inhibit -calpain activity detected by cleavage of N-succinyl-
LY-AMC at 150 M. We found that the Ct12p20 peptide inhib-
ited calpain activity with an apparent IC50 of 106 M and with
100% inhibition at 1 mM (Fig. 6D). The scramble peptide pro-
duced no inhibition at 1 mM. Interestingly, a Ct12p20 peptide
in which leucine 168 was substituted by lysine (Ct12p20-
L168K) produced no inhibition at 1 mM. These results further
suggested that the interaction between Ct12p20 and calpain
was of low affinity but specific.
We next studied the calpain-dependent cleavage of recombi-
nant histidine tagged procaspase-3 and caspase-3 p20 subunit,
which were radiolabeled using in vitro translation assay in
presence of [35S]methionine (Fig. 7). The procaspase-3 mi-
grated at an apparent molecular mass of 36 kDa corresponding
to the theoretical molecular mass of 32 kDa of procaspase-3
plus the histidine tag. The 36-kDa procaspase-3 was cleaved by
-calpain in vitro, leading to a main breakdown product of 30
kDa, consistent with the cleavage site in the N-terminal part of
procaspase-3 reported previously (24, 27). We then tested
whether calpain also cleaved the p20 active subunit. To do so,
we first obtained a radiolabeled caspase-3 p20 subunit after
maturation of the procaspase-3 by caspase-8 (Fig. 7). The p20
subunit migrated near 19 kDa. A larger peptide of 25 kDa
was also produced, possibly corresponding to procaspase-3
cleaved only in its N-terminal domain (Asp-28). Subsequent
incubation of the p20 subunit of caspase-3 with calpain pro-
duced the disappearance of the 19-kDa band leading to a
smaller fragment of 18 kDa. Note that we could not resolve
proteins of molecular mass lower than 12 kDa that may be
generated in our experimental conditions.
Altogether, we demonstrated that the p20 active form of
caspase-3 is cleaved by calpain near its catalytic site, inacti-
vating caspase-3 proteolytic activity.
FIG. 3. 3NP treatment induces a de-
crease of active caspase-3 and an in-
crease in calpain activity in vivo. Stri-
atal cytosol fractions were prepared from
control (CTRL) and 3NP-treated rats (i.e.
days 1–5). A, SDS-PAGE followed by
Western blot (chemiluminescence detec-
tion with amplification) for active
caspase-3 of striatal cytosol fractions. B,
decreased caspase 3-like DEVDase pro-
teolytic activity during 3NP treatment. C,
SDS-PAGE followed by Western blot for
fodrin of membrane fractions prepared
from striatum of control (CTRL) and 3NP-
treated rats. Note the typical calpain-me-
diated breakdown products of fodrin ap-
pearing as a doublet (150/145 kDa). D,
Ca2-dependent calpain-related proteo-
lytic activity (cleavage of N-succinyl-LY-
AMC) increases significantly in the stria-
tum of 3NP-treated animals. Note that
the increase in calpain activity is followed
by progressive decline in immunoreactiv-
ity for the caspase-3 p20 subunit and
DEVDase-related activity. Data are
means  S.E. *, p  0.02; **, p  0.0003
compared with control, ANOVA, and post-
hoc Scheffe´ F-test.
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DISCUSSION
In this study, we used our chronic 3NP intoxication model of
neurodegeneration in rat to further study cellular changes and
biochemical pathways leading to striatal cell death during mi-
tochondrial defects (22). We showed that cytochrome c redis-
tribution and transient caspase-9 processing occur at the be-
ginning of the 3NP treatment. The fact that these events
occurred 2–3 days before cell degeneration (i.e. nuclei fragmen-
tation) suggest that in vivo primary blockade of complex II
activity by 3NP leads to early activation of the so-called caspase-
dependent mitochondrial pathway as seen in bona fide apopto-
FIG. 4. Blockade of calpain by Cl-1 modifies the 3NP-induced
loss of endogenous processed caspase-3 and caspase-9 in vivo.
Striatal extracts from control rats (CTRL) and from rats treated with
3NP for 5 days (3NP) or with 3NP plus calpain inhibitor I (3NPCl-1)
were analyzed by Western blot for caspase-9 (A) and caspase-3 (B) and
for caspase-3 DEVDase activity (C). Intracerebral delivery of CI-I in
3NP rats induced an accumulation of the endogenous active caspase-9
and prevented the loss of active caspase-3 immunoreactivity and
caspase-3 activity in the striatum. Data are means  S.E. *, p  0.006
compared with control, ANOVA, and post-hoc Scheffe´ F-test.
FIG. 5. Effects of cell-free extracts from 3NP-treated rats on
recombinant caspases-3 and -9. Cell-free extracts prepared from
striatum of control (CTRL extract) or 3NP-treated rats (3NP extract)
treated or not with calpain inhibitor I (Cl-1) in vivo were incubated with
recombinant caspase-3 or -9 (Rec. C9 and Rec. C3, respectively). Cell-
free extracts from 3NP-treated rats were incubated with or without
calpain inhibitor z-LL-CHO (z-LL). Following SDS-PAGE, we per-
formed Western blots for caspase-9 (A) and caspase-3 (B, upper panel).
For caspase 3 blots, we used an antibody selectively recognizing the 12
C-terminal amino acids of the p20 subunit. The DEVDase proteolytic
activity of active recombinant caspase-3 was also evaluated in the same
samples as described above (B, lower panel). Note that recombinant
caspases-3 and -9 remain stable in the presence of CTRL extract.
Recombinant caspases-3 and -9 are degraded by extracts of 3NP-treated
rats. This degradation is prevented in vitro by z-LL or with striatal
extracts prepared from rats treated with Cl-1 in vivo. Data are the
means  S.E. *, p  0.003 compared with control and CI-1, ANOVA,
and post-hoc Scheffe´ F-test.
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sis. In apoptosis or accidental cell death, caspase-9 activation is
often followed by downstream activation of the effector
caspase-3 (36). Unexpectedly, this study shows that this is not
the case in our 3NP model of striatal neurodegeneration.
In the brain of control rats, we detected base-line or “physi-
ological” levels of the activated caspase-3 p20-subunit as well
as DEVDase activity that were similar to baseline levels of
active caspase-3 shown by others (37). Little is known regard-
ing the “physiological” levels of caspase activity in the normal
adult rat brain. One possibility is that apparent basal levels of
active caspase-3 in the normal brain is due, at least in part, to
post-mortem processing of the brain tissue. However, we found
caspase-3-related DEVDase activity in rat striatal samples
prepared using freeze-clamp methods and we detected the
caspase-3 p20 subunit by Western blot in the striatum of non-
human primates fixed using transcardial paraformaldehyde
perfusion.3 These procedures minimize post-mortem modifica-
tion of proteins. In line with this finding, there is some evidence
of caspase activity in normal brain related to synaptic plas-
ticity (38) and to physiological processing of proteins such as
huntingtin (39).
The 3NP treatment produced neither an increase of
caspase-3 p20 concentration nor caspase-3-related activity. On
the contrary, levels of detectable p20 subunit and DEVDase
activity decreased during the 3NP treatment. We found that
the apparent loss of the active caspase-3 p20 subunit followed
a prominent increase in calpain activity, another important cell
death effector protease (35). Thus, we examined whether the
regulation of caspases-9 and -3 could involve calpain.
In this respect, we found that purified calpain could degrade
processed caspase-9 subunit p34 in vitro. Additionally, using
cell-free extracts, we showed that endogenous active calpain
from the striatum of 3NP-treated rats could degrade the pro-
cessed recombinant caspase 9 p34 subunit. This is consistent
with results reported by others (25, 26), which showed that in
vitro purified calpain cleaved procaspase-9 at four main cleav-
age sites including one in the p34 subunit prodomain. These
authors showed that calpain cleaves procaspase-9, hampering
subsequent processing into its active form. In the 3NP model,
caspase-9 activation is transiently detected on day 3, levels of
p34 subunit of processed caspase-9 returning to base-line levels
3 M. F. Beal, L. Yang, F. Conde´, N. Bizat, J.-M. Hermel, P. Hantraye,
and E. Brouillet, unpublished results.
FIG. 6. -Calpain-degrades active forms of caspase-3 and caspase-9 in vitro. After in vitro incubation of recombinant caspase-3 (Rec. C3)
and -9 (Rec. C9) with purified -calpain with or without calpain inhibitor z-LL-CHO (z-LL), we analyzed the digestion products by SDS-PAGE
followed by Western blot for activated caspase-9 revealing the p34 subunit (A) and for activated caspase-3 revealing the p20 subunit appearing as
p17-p19 doublet (B). No smaller caspase-9 fragment was detected below 34 kDa. No smaller caspase-3 fragment was detected below 17 kDa. The
antibody directed against active caspase-3 recognizes the 12 C-terminal amino acids of p20. Note that caspase-9 p34 and caspase-3 p20 are
degraded by incubation with -calpain. This degradation is prevented by the incubation of -calpain with its inhibitor z-LL. C, the DEVDase
activity of Rec. C3 is almost suppressed by calpain. This calpain effect is prevented by z-LL. Assays were performed in triplicate. D, representation
of the p20 subunit of active caspase-3 (p20) and sequence of the 12 amino acids of its Ct12p20 domain against which the antibody Ab1797 was
raised. Sequence of the modified Ct12p20 peptide with the leucine 168 substituted for a lysine (Ct12p20-L168K). E, concentration-response
inhibition of calpain activity by the Ct12p20 peptide. The IC50 of this inhibition (106 M) suggests the specific interaction of the C-terminal domain
of caspase-3 with calpain. F, activity of purified -calpain in presence of Ct12p20, Ct12p20-L168K, and the scrambled peptide. Only Ct12p20 at
1 mM inhibits -calpain activity. Results are expressed as mean  S.E. *, p  0.005 compared with control, ANOVA, and post-hoc Scheffe´ F-test.
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on day 5. Interestingly, we showed that blocking calpain activ-
ity in vivo during 3NP treatment led to an increase in the levels
of p34 on day 5 as compared with control levels. This finding
strongly suggests that during 3NP-induced degeneration, cal-
pain hampers caspase-9 activation (Fig. 8). To our knowledge,
this is the first evidence that calpain could down-regulate the
activation of caspase-9 in the living brain during a neurode-
generative process.
The calpain-mediated inactivation of caspase-9 may be at
least partly responsible for the down-regulation of active
caspase-3 in the 3NP model. However, we identified another
potential mechanism that could also contribute to hamper
caspase-3 activation. We showed that the active form of
caspase-3 was cleaved by calpain, leading to a loss of its DEV-
Dase activity. Western blot analysis of p20 breakdown products
using different antibodies showed that the p20 subunit was
cleaved in its C-terminal region. Cleavage of p20 by calpain
was confirmed by experiments using radiolabeled recombinant
p20. These data together with the analysis of the radiolabeled
recombinant p20-cleaved products by calpain and the inhibi-
tion of calpain activity by the 12 C-terminal amino-acids of p20
led us to propose that the calpain cleavage site on p20 is located
at 10 amino acids from Asp-175 of the C terminus. This is
consistent with the resulting loss of activity, because the cys-
teine of the catalytic site is very close (Cys-163). Although
calpain lacks a strict consensus cleavage site, calpain often
cleaves its substrates in position P2 of a leucine, isoleucine, or
valine (35). Therefore, it could be assumed that calpain cleaves
p20 at position Leu-168 and this is supported by our observa-
tion that the L168K substitution blocks the ability of the C-
terminal domain of p20 to inhibit -calpain. Unfortunately, the
precise calpain cleavage site on p20 is not established and we
did not succeed in isolating the small breakdown product of p20
after calpain digestion for N-terminal sequencing. The exist-
ence of one calpain-dependent cleavage site in the N-terminal
prodomain of caspase-3 (residue Ser-7) was described previ-
ously by Wolf and collaborators (27). It should be noted that the
calpain cleavage site in caspase-3 p20 is not sensitive to calpain
in the procaspase-3. On the other hand, three-dimensional
reconstruction of active caspase-3 structure indicates that the
C-terminal region of p20 is highly exposed to the external
environment (40), which is compatible with the possibility that
calpain may easily interact with this domain. In consideration
of all of the above, our study demonstrates that calpain cleaves
the active p20 subunit of caspase-3 at a site near its C-terminal
region but not the p20 domain of the procaspase-3.
Our data further documents the potential mechanisms un-
derlying a cross-talk between calpain and caspases-9 and -3
pathway. During the cell death process involving calpain, ac-
tivation of caspases-3 and -9 could be regulated by inactivation
FIG. 7. Caspase-3 is cleaved by calpain in vitro. Histidine-tagged
procaspase-3 (36 kDa) was labeled with [35S]methionine and incubated
with calpain and/or caspase-8 in the presence of Cl-1 or not. Upper
panel, the cleaved products were resolved by a SDS-PAGE and then
dried and exposed for autoradiography. Procaspase-3 (1) is cleaved
(open arrows) by caspase-8 (C8) to produce an active caspase-3 p20
fragment (3). This caspase-3 p20 subunit is further cleaved by calpain
(black arrows) into a breakdown product of 18 kDa (4). Calpain also
cleaved the procaspase-3 to produce a 30-kDa peptide (2). The caspase-8
cleavage of procaspase-3 (open arrows) generates a larger peptide of
25 kDa (asterisk) that seems to be unstable and that is further cleaved
to generate the p20 active form. This 25-kDa peptide may possibly
correspond to procaspase-3 cleaved only in its N-terminal domain (Asp-
28). The nonspecific (N.S.) band resolved at 28 kDa appears to be a
contaminant peptide unrelated to caspase-3. The cleavage of caspase-3
p20 by calpain is inhibited by adding Cl-1 (10 M). Numbers in the lower
panel correspond to the aligned schemes of peptides present in the
experiment described above. Dashed lines represent putative calpain
cleavage site.
FIG. 8. Scheme pathways of the chronic 3NP toxicity. 3NP (1)
specifically blocks the mitochondrial succinate dehydrogenase leading
to the activation of two parallel pathways, the mitochondrial pathway
involving caspase-9 (2) and the calpain pathway triggered by cytoplas-
mic [Ca2] increase (3). Activated caspase-9 would process the effector
caspase-3, which should lead to apoptotic cell death. In parallel, the
increase in intracellular [Ca2] concentration could activate -calpain
and possibly m-calpain at the same time. The calpains then may block
the caspase-9/-3 apoptotic pathways at least in part through cleavage of
the active caspases (4) and lead to cell death through still unraveled
mechanisms (5).
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of their proform, blocking further maturation (25–27). Our
results suggest that, in addition, calpain can directly cleave the
active/processed form of caspase-3, thus adding a new fork to
the complicated pathways leading to cell death (Fig. 8). This
calpain-mediated cleavage of p20 could at least partly explain
how calpain could predominate during striatal cell death in-
duced by 3NP (22) or other toxins such as NMDA (26).
It is possible that the novel mechanism through which cal-
pain regulates directly caspase-3 proteolytic activity could be
involved in neurodegenerative disorders associated with par-
tial mitochondrial defects. Given that 3NP toxicity replicates
many biochemical, histological, and behavioral features of HD
in laboratory animals (21), it is tempting to speculate that the
caspase-9/-3 pathway may be down-regulated by calpain in the
striatum of HD patients. This hypothesis awaits confirmation
by observations on human samples.
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